Graybug Vision Inc (GRAY): Price and Financial Metrics
GET POWR RATINGS... FREE!
GRAY Stock Price Chart Interactive Chart >
GRAY Price/Volume Stats
| Current price | $3.73 | 52-week high | $37.88 |
| Prev. close | $3.56 | 52-week low | $3.43 |
| Day low | $3.52 | Volume | 144,679 |
| Day high | $3.75 | Avg. volume | 1,035,303 |
| 50-day MA | $3.97 | Dividend yield | N/A |
| 200-day MA | $11.35 | Market Cap | 79.39M |
Graybug Vision Inc (GRAY) Company Bio
GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.
Latest GRAY News From Around the Web
Below are the latest news stories about Graybug Vision Inc that investors may wish to consider to help them evaluate GRAY as an investment opportunity.
Graybug Vision to Participate in the Cantor Virtual Global Healthcare ConferenceBALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 11:20 a.m. ET / 8:20 a.m. PT. Dr. Guerard will provide a corporate update, in |
A Look at Graybug Vision’s Risk FactorsGraybug Vision (GRAY) is a biotech company that develops transformational therapies for the treatment of retinal and optic nerve illnesses. Let’s take a look at the eye disease drug maker’s latest financial performance and risk factors. (See Graybug Vision stock charts on TipRanks) Graybug Vision’s Financial Performance Graybug Vision reported a net loss of $7.7 million in the second quarter versus a net loss of $5.9 million in the year-ago quarter. General and administrative expenses jumped 157% to $3.6 million, while research and development expenses decreased 8.7% to $4.2 million on a year-over-year basis. |
Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate DevelopmentsREDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the three and six months ended June 30, 2021. |
Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate DevelopmentsREDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the three and six months ended June 30, 2021. Recent Corporate Developments Completed six-month extended observation period of ALTISSIMO Phase 2b trial in wet AMD— |
Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual ConferenceREDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a panel discussion titled Goldeneye at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021 at 9:45 a.m. ET / 6:45 a.m. PT. |
GRAY Price Returns
| 1-mo | -1.06% |
| 3-mo | -28.27% |
| 6-mo | -36.67% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -87.15% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...